石四藥集團(02005.HK)前三季度純利增長17.2%至7.59億港元 安瓿小水針營業額大增256%
格隆匯10月21日丨石四藥集團(02005.HK)公佈,本集團大部份銷售於中國進行並以人民幣計值。按人民幣計,本集團於截至2019年9月30日止9個月未經審計營業額較2018年同期增加15.3%至約人民幣29.54億元。然而,當人民幣換算為港元,人民幣較2018年同期貶值約4.6%。因此,按港元計,期間本集團未經審核營業額較2018年同期增加10.0%至約33.80億港元,其中安瓿小水針產品營業額2.62億港元,同比大增256%。
按港元計,期間本集團未經審核毛利約為20.72億港元,較2018年同期增加8.8%。期間本集團未經審核本公司股東應占溢利較2018年同期增加17.2%至約7.59億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.